Tanja Obradovic, Oncology Medical Strategy Adviser, Clinical Drug Development Expert, shared a post by HopeAI on LinkedIn, adding:
“Great opportunity for drug development community to stay on top of trends and news about AI inroads by following HopeAI podcasts as we are starting very dynamic 2026.”
Quoting HopeAI‘s post:
“We’re excited to officially launch the HopeAI video podcast series – HopeTalk.
At HopeAI, we focus on one core question:
Where does AI truly change outcomes in drug development – and where does it still fall short?
HopeTalk is our video podcast exploring that question through candid, unscripted conversations with leaders across biopharma, clinical development, healthcare AI, venture capital, and patient advocacy – focused on how real decisions translate into patient impact.
For our first episode, we sat down with Tanja Obradovic, who recently joined HopeAI as a Scientific Advisor. Dr. Obradovic is a globally recognized leader in oncology clinical development and played a key role in the design and development of KEYTRUDA (pembrolizumab) HCP.
In this conversation, we examine a critical industry shift: while AI adoption has accelerated in discovery and post-approval settings, clinical development – the decision-heavy middle – remains the true bottleneck.
We discuss why decision-making, not paperwork, ultimately determines speed, cost, and outcomes – and what responsible AI innovation must look like in this most human-dependent phase of drug development.
This is just the beginning. More conversations coming with the people shaping the future of clinical research.
Watch Episode One.”
More posts featuring Tanja Obradovic on OncoDaily.